TNGX at a glance
Tango Therapeutics, Inc. (TNGX, SEC CIK 1819133) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Tango Therapeutics, Inc. (TNGX) reported revenue of $62.4 million (up 48.3% from FY2024) and a net loss of $101.6 million. Diluted EPS was -$0.87.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Tango Therapeutics, Inc. (TNGX) shares worth $2.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Crystal Adam on October 1, 2026 of 600 shares at $25.32 per share.
- In the last 90 days, TNGX insiders reported 0 open-market purchases ($0) and 8 open-market sales ($2.2M) on Form 4, a net sale of $2.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $62.4M
- +48.3% vs prior year
- Insiders · 90 days
- 0 buys · 8 sells
- Net −$2.2M
- 13F holders
- 29 funds
- $2.0B · +2 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Regulatory risk: FDA clinical trial approvals and safety profiling of PRMT5 inhibitors vopimetostat and TNG456 ongoing with multiple Phase 1/2 trials active in 2026
- Macroeconomic exposure: Cash runway of $343.1M as of Dec 31, 2025 expected to fund operations only into 2028, requiring substantial additional capital raises
- Operational vulnerability: Dependence on third-party CROs and manufacturers for preclinical and clinical trial execution and drug supply management
- Competitive risk: Combination therapy trials with Revolution Medicines’ RAS inhibitors and Erasca’s ERAS-0015 molecular glue amid oncology market competition
- Financial risk: Net losses averaging ~$111M in 2025 with accumulated deficit $603.2M, no current product revenue, reliance on equity financing and collaboration revenue
AI summary of the TNGX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes to 2025 Form 10-K risk factors, per June 30, 2026 10-Q
- Carried-forward business risk: additional unknown or currently immaterial risks could materially harm results
- No newly added regulatory, legal, compliance, operational, competitive, or financial risk identified this quarter
AI summary of the TNGX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- ATM offering capacity increased to $400 million, including $35.61 million carried over from the prior prospectus
- Approximately $64.39 million already sold under the prior $100 million authorization
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Press release issued August 11, 2026 and furnished as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 2026 revenue $0; net loss $55.3M, or $0.37 per share, versus $38.9M and $0.35 previously
- Cash, equivalents and marketable securities $1.0B, supporting planned Phase 3 advancement and commercialization preparation
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Dr. Weber’s departure triggers salary continuation through December 31, 2026 and COBRA reimbursement through that date
- Full acceleration of outstanding options and RSUs subject to Compensation Committee approval
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, making disclosed information available to investors
- Exhibit not deemed “filed” under Exchange Act Section 18, limiting statutory liability exposure
Item EX-99.1: Item EX-99.1
- Executive Chair Barbara Weber stepping down to pursue other opportunities
- Leadership transition creates potential governance and strategic continuity risk for clinical-stage biotech
AI summaries of TNGX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TNGX
Don't miss the next TNGX filing
- Alerts as it files. A push when TNGX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TNGX, by share count.
- Ask anything. An AI agent that reads every TNGX filing and answers with sources.
TNGX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Crystal Adam | M | Oct 1, 2026 | 27,000 | - |
| Crystal Adam | Sell | Oct 1, 2026 | 600 | $25.32 |
| Crystal Adam | M | Oct 1, 2026 | 27,000 | $5.20 |
| Crystal Adam | Sell | Oct 1, 2026 | 26,400 | $24.45 |
| Newcomb Jessica | Sell | Sep 22, 2026 | 700 | $22.80 |
| Newcomb Jessica | Sell | Sep 22, 2026 | 2,400 | $25.17 |
| Newcomb Jessica | Sell | Sep 22, 2026 | 5,100 | $23.97 |
| Crystal Adam | Sell | Sep 1, 2026 | 27,000 | $22.37 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $42.1M | $62.4M |
| Operating Income | - | -$145.6M | -$111.3M |
| Net Income | -$101.7M | -$130.3M | -$101.6M |
| Op. Margin | - | -346.1% | -178.4% |
| Net Margin | - | -309.7% | -162.9% |
| Balance Sheet | |||
| Total Assets | $402.6M | $316.5M | $398.7M |
| Equity | - | $199.5M | $346.2M |
| ROE | - | -65.3% | -29.3% |
| Per Share | |||
| EPS | $-1.08 | $-1.19 | $-0.87 |
| Cash Flow | |||
| Operating CF | - | -$131.5M | -$138.9M |
| CapEx | $1.5M | $754K | $1.0M |
Source: XBRL data in Tango Therapeutics, Inc. (TNGX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TNGX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $2.01B |
| Q1 2026 | 27 | $884.2M |
| Q4 2025 | 21 | $312.9M |
| Q3 2025 | 24 | $222.2M |
| Q2 2025 | 24 | $103.4M |
| Q1 2025 | 23 | $19.4M |
| Q4 2024 | 18 | $42.1M |
| Q3 2024 | 12 | $47.0M |
- T. Rowe Price Group+5.46M (+614%)
- Goldman Sachs Group+4.90M (+97%)
- BlackRock+3.69M (+42%)
- FMR LLC (Fidelity)+2.43M (+25%)
- JPMorgan Chase & Co+1.35M (+2006%)
- Morgan Stanley−966.7K (-65%)
- Ameriprise Financial−199.8K (-39%)
- Invesco Ltd−117.7K (-20%)
- AQR Capital Management−16.3K (-15%)
- Dimensional Fund Advisors−1.0K (-0%)
- Renaissance Technologies LLC+748.3K
- Raymond James Financial+170.3K
- Principal Financial Group+10.8K
- Fifth Third Bancorp+122
- Allstate−32.0K
- Mangrove Partners−12.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 178 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TNGX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 8, 2026 | - | Analysis | |
| SC 13G | May 6, 2026 | - | - | |
| 4 | May 5, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
TNGX SEC filings: frequently asked questions
Are TNGX insiders buying or selling?
In the last 90 days, Tango Therapeutics, Inc. (TNGX) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $2.2 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TNGX stock?
As of June 30, 2026, the largest Tango Therapeutics, Inc. (TNGX) holders among the 13F filers tracked by SignalX were BlackRock ($388.8 million), FMR LLC (Fidelity) ($385.5 million), Goldman Sachs Group ($312.0 million), T. Rowe Price Group ($198.5 million), State Street Corp ($186.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TNGX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Tango Therapeutics, Inc. (TNGX) reported revenue of $62.4 million (up 48.3% from FY2024) and a net loss of $101.6 million. Diluted EPS was -$0.87. The figures come from the XBRL data in the 10-K.
What are the main risks in TNGX's latest 10-K?
In the 10-K filed March 5, 2026, Tango Therapeutics, Inc. (TNGX) flagged: Regulatory risk: FDA clinical trial approvals and safety profiling of PRMT5 inhibitors vopimetostat and TNG456 ongoing with multiple Phase 1/2 trials active in 2026. Macroeconomic exposure: Cash runway of $343.1M as of Dec 31, 2025 expected to fund operations only into 2028, requiring substantial additional capital raises. (AI summary of the Risk Factors section.)
What did TNGX report in its latest 8-K?
Tango Therapeutics, Inc. (TNGX) filed an 8-K on August 11, 2026 reporting Item 8.01 (Other Events). ATM offering capacity increased to $400 million, including $35.61 million carried over from the prior prospectus.
What are the latest TNGX SEC filings?
Tango Therapeutics, Inc. (TNGX) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on October 5, 2026.
What is TNGX's SEC CIK number?
Tango Therapeutics, Inc. (TNGX)'s SEC Central Index Key (CIK) is 1819133. EDGAR lists every TNGX filing under that number.
Ask anything about TNGX
The research agent reads TNGX's filings, financials, insider trades and 13F holders, then answers with sources.